Media stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cumberland Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.7943056019979 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Cumberland Pharmaceuticals (NASDAQ:CPIX) traded up 2.53% on Friday, hitting $6.90. The stock had a trading volume of 7,464 shares. The firm’s market cap is $109.68 million. Cumberland Pharmaceuticals has a 1-year low of $4.43 and a 1-year high of $7.49. The firm’s 50-day moving average price is $6.87 and its 200-day moving average price is $6.51.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 19.57% and a negative return on equity of 0.13%. The business had revenue of $8.67 million during the quarter. On average, equities research analysts predict that Cumberland Pharmaceuticals will post $0.09 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cumberland Pharmaceuticals (CPIX) Earns Daily News Sentiment Rating of 0.12” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.